India Unit Of Sanofi-Aventis Told By WHO 5-Disease Vaccine Has Problem
This article was originally published in PharmAsia News
Executive Summary
The Indian subsidiary of French drug maker Sanofi-Aventis has been told by the United Nations it was suspending purchase and use of the Shan5 vaccine for five diseases, including tetanus
You may also be interested in...
WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010
MUMBAI - French drug maker Sanofi Aventis is faced with an unexpected crisis situation over large quantities of product recall ordered by the World Health Organization for pediatric pentavalent vaccines manufactured by its newly acquired Indian vaccines unit - Shantha Biotechnics
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.